These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2574230)

  • 61. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Models for in vivo kinetic interactions of dopamine D2-neuroreceptors and 3-(2'-[18F]fluoroethyl)spiperone examined with positron emission tomography.
    Bahn MM; Huang SC; Hawkins RA; Satyamurthy N; Hoffman JM; Barrio JR; Mazziotta JC; Phelps ME
    J Cereb Blood Flow Metab; 1989 Dec; 9(6):840-9. PubMed ID: 2531147
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long term treatment of tardive dyskinesia.
    Jus A; Jus K; Fontaine P
    J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
    Butler B; Bech P
    Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand; 1988 Apr; 77(4):369-78. PubMed ID: 2898870
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Tardive dyskinesia: I. Physiopathology and treatment].
    Andrade LA; Bertolucci PH; Pereira JS
    Arq Neuropsiquiatr; 1984 Dec; 42(4):362-70. PubMed ID: 6152578
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The course of tardive dyskinesia in newly treated psychogeriatric patients.
    Yassa R
    Acta Psychiatr Scand; 1991 May; 83(5):347-9. PubMed ID: 1677231
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics.
    Chouinard G; Steinberg S
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):571-8. PubMed ID: 6131490
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tardive dyskinesia: natural history studies assist the pursuit of preventive therapies.
    Stahl SM
    Psychol Med; 1986 Aug; 16(3):491-4. PubMed ID: 2876449
    [No Abstract]   [Full Text] [Related]  

  • 73. Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder.
    Steiner W; Laporta M; Chouinard G
    Acta Psychiatr Scand; 1990 May; 81(5):437-40. PubMed ID: 1972608
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage.
    Seeman P
    Acta Psychiatr Scand Suppl; 1990; 358():14-20. PubMed ID: 1978482
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Levodopa and receptor sensitivity modification in tardive dyskinesia.
    Casey DE; Gerlach J; Bjørndal N
    Psychopharmacology (Berl); 1982; 78(1):89-92. PubMed ID: 6128757
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Striatal [11C]-N-methyl-spiperone binding in patients with focal dystonia (torticollis) using positron emission tomography.
    Leenders K; Hartvig P; Forsgren L; Holmgren G; Almay B; Eckernäs SA; Lundqvist H; Långström B
    J Neural Transm Park Dis Dement Sect; 1993; 5(2):79-87. PubMed ID: 8101445
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chemical and structural changes in the brain in patients with movement disorder.
    Cross AJ; Crow TJ; Ferrier IN; Johnson JA; Johnstone EC; Owen F; Owens DG; Poulter M
    Psychopharmacology Suppl; 1985; 2():104-10. PubMed ID: 2860653
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapeutic trials in tardive dyskinesia.
    Villeneuve A
    Can Psychiatr Assoc J; 1978 Oct; 23(6):411-5. PubMed ID: 30534
    [TBL] [Abstract][Full Text] [Related]  

  • 79. EMG patterns in abnormal involuntary movements induced by neuroleptics.
    Bathien N; Koutlidis RM; Rondot P
    J Neurol Neurosurg Psychiatry; 1984 Sep; 47(9):1002-8. PubMed ID: 6148381
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy.
    Lieberman JA; Alvir J; Mukherjee S; Kane JM
    Arch Gen Psychiatry; 1989 Oct; 46(10):908-13. PubMed ID: 2572205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.